A systematic analysis of predicted MiR-31-targets identifies a diagnostic and prognostic signature for lung cancer

Biomedicine and Pharmacotherapy

Volumn 68, Issue 4, 2014, Pages 419-427

  Gao, Wen ^a   Liu, Lingxiang ^a   Xu, Jing ^a   Shao, Qianwen ^a   Liu, Yiqian ^a   Zeng, Huazong ^b   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Shanghai Sensichip Infotech CoLtd   (China)

Author keywords

Lung cancer; MiR 31; Systematic analysis

Indexed keywords

CHEMOKINE; CYTOCHROME P450; MICRORNA 31; MITOGEN ACTIVATED PROTEIN KINASE; MICRORNA; MIRN31 MICRORNA, HUMAN; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; GENE ONTOLOGY; GENE TARGETING; HUMAN; LUNG CANCER; METABOLISM; NATURAL LANGUAGE PROCESSING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; DISEASE COURSE; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS;

APOPTOSIS; CHEMOKINES; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901634639     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.009     Document Type: Article

References (85)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Miller Y.E. Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol 2005, 33:216-223.
3. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
4. Garzon R., Fabbri M., Cimmino A., Calin G.A., Croce C.M. MicroRNA expression and function in cancer. Trends Mol Med 2006, 12:580-587.
5. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
6. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
7. Sempere L.F., Kauppinen S. Translational implications of microRNAs in clinical diagnostics and therapeutics. Handbook of cell signaling 2009, 2965-2981. Academic Press, Oxford, UK. 2nd ed. R.A. Bradshaw, E.A. Dennis (Eds.).
8. Landgraf P., Rusu M., Sheridan R., Sewer A., Iovino N., Aravin A., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129:1401-1414.
9. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27:91-105.
10. Valastyan S., Weinberg R.A. miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 2010, 9:2124-2129.
11. Tan X., Qin W., Zhang L., Hang J., Li B., Zhang C., et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011, 17:6802-6811.
12. Liu C.J., Tsai M.M., Hung P.S., Kao S.Y., Liu T.Y., Wu K.J., et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010, 70:1635-1644.
13. Gao W., Xu J., Liu L., Shen H., Zeng H., Shu Y. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother 2012, 66:21-28.
14. Settles B. ABNER: an open source tool for automatically tagging genes, proteins and other entity names in text. Bioinformatics 2005, 21:3191-3192.
15. Smith L., Tanabe L.K., Ando R.J., Kuo C.J., Chung I.F., Hsu C.N., et al. Overview of BioCreative II gene mention recognition. Genome Biol 2008, 9:S2.
16. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
17. Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., et al. Combinatorial microRNA target predictions. Nat Genet 2005, 37:495-500.
18. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
19. Morgan M, Falcon S, Gentleman R. GSEABase: gene set enrichment data structures and methods. R package version 1.4.0.
20. Kanehisa M., Araki M., Goto S., Hattori M., Hirakawa M., Itoh M., et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008, 36:D480-D484.
21. Dahlquist K.D., Salomonis N., Vranizan K., Lawlor S.C., Conklin B.R. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 2002, 31:19-20.
22. Ogata H., Goto S., Fujibuchi W., Kanehisa M. Computation with the KEGG pathway database. Biosystems 1998, 47:119-128.
23. Mewes H.W., Albermann K., Heumann K., Liebl S., Pfeiffer F. MIPS: a database for protein sequences, homology data and yeast genome information. Nucleic Acids Res 1997, 25:28-30.
24. Jenssen T.K., Laegreid A., Komorowski J., Hovig E. A literature network of human genes for high-throughput analysis of gene expression. Nat Genet 2001, 28:21-28.
25. Stapley B.J., Benoit G. Biobibliometrics: information retrieval and visualization from co-occurrences of gene names in Medline abstracts. Pac Symp Biocomput 2000, 529-540.
26. Hooper S.D., Bork P. Medusa: a simple tool for interaction graph analysis. Bioinformatics 2005, 21:4432-4433.
27. Seo C.H., Kim J.R., Kim M.S., Cho K.H. Hub genes with positive feedbacks function as master switches in developmental gene regulatory networks. Bioinformatics 2009, 25:1898-1904.
28. Schmittgen T.D. miR-31: a master regulator of metastasis?. Future Oncol 2010, 6:17-20.
29. Gao W., Lu X., Liu L., Xu J., Feng D., Shu Y. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012, 13:330-340.
30. Lindow M., Gorodkin J. Principles and limitations of computational microRNA gene and target finding. DNA Cell Biol 2007, 26:339-351.
31. Li J., Musso G., Zhang Z. Preferential regulation of duplicated genes by microRNAs in mammals. Genome Biol 2008, 9:R132.
32. Watanabe Y., Tomita M., Kanai A. Computational methods for microRNA target prediction. Methods Enzymol 2007, 427:65-86.
33. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szász A.M., Wang Z.C., et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
34. Creighton C.L., Fountain M.D., Yu Z., Nagaraja A.K., Zhu H., Khan M., et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 2010, 70:1906-1915.
35. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009, 27:5848-5856.
36. Mascaux C., Laes J.F., Anthoine G., Haller A., Ninane V., Burny A., et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J 2009, 33:352-359.
37. Williams G.H., Stoeber K. The cell cycle and cancer. J Pathol 2012, 226:352-364.
38. Xing D., Qi J., Miao X., Lu W., Tan W., Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer 2002, 100:600-605.
39. Trivedi R.N., Almeida K.H., Fornsaglio J.L., Schamus S., Sobol R.W. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005, 65:6394-6400.
40. Kang J.M., Park S., Kim S.J., Hong H.Y., Jeong J., Kim H.S., et al. CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-β signaling. Oncogene 2012, 31:5123-5131.
41. Langdon W.Y., Hartley J.W., Klinken S.P., Ruscetti S.K., Morse H.C. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci U S A 1989, 86:1168-1172.
42. Pillé J.Y., Denoyelle C., Varet J., Bertrand J.R., Soria J., Opolon P., et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005, 11:267-274.
43. Molinari C., Medri L., Follo M.Y., Piazzi M., Mariani G.A., Calistri D., et al. PI-PLCβ1 gene copy number alterations in breast cancer. Oncol Rep 2012, 27:403-408.
44. Gowardhan B., Douglas D.A., Mathers M.E., McKie A.B., McCracken S.R., Robson C.N., et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005, 92:320-327.
45. Meijer D., Sieuwerts A.M., Look M.P., van Agthoven T., Foekens J.A., Dorssers L.C. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 2008, 15:101-111.
46. Schmid M.C., Avraamides C.J., Foubert P., Shaked Y., Kang S.W., Kerbel R.S., et al. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res 2011, 71:6965-6975.
47. Mitamura T., Watari H., Wang L., Kanno H., Hassan M.K., Miyazaki M., et al. Down regulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2013, 2:e40.
48. Asangani I.A., Harms P.W., Dodson L., Pandhi M., Kunju L.P., Maher C.A., et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012, 3:1011-1025.
49. Borczuk A.C., Gorenstein L., Walter K.L., Assaad A.A., Wang L., Powell C.A. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003, 163:1949-1960.
50. Laroche-Clary A., Le Morvan V., Yamori T., Robert J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. Mol Cancer Ther 2010, 9:3315-3321.
51. Alfieri R.R., Galetti M., Tramonti S., Andreoli R., Mozzoni P., Cavazzoni A., et al. Metabolism of the EGFR tyrosine kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non-small cell lung cancer cell lines. Mol Cancer 2011, 10:143.
52. Husgafvel-Pursiainen K. Genotoxicity of environmental tobacco smoke: a review. Mutat Res 2004, 567:427-445.
53. Lam T.K., Rotunno M., Lubin J.H., Wacholder S., Consonni D., Pesatori A.C., et al. Dietary quercetin, quercetin-gene interaction, metabolic gene expression in lung tissue and lung cancer risk. Carcinogenesis 2010, 31:634-642.
54. Smit E.F., Socinski M.A., Mullaney B.P., Myrand S.P., Scagliotti G.V., Lorigan P., et al. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Ann Oncol 2012, 23:1723-1729.
55. Adjei A.A., Mandrekar S.J., Dy G.K., Molina J.R., Adjei A.A., Gandara D.R., et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010, 28:614-619.
56. Fujimori S., Abe Y., Nishi M., Hamamoto A., Inoue Y., Ohnishi Y., et al. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo. Oncol Rep 2005, 14:421-424.
57. Inoue Y., Tomisawa M., Yamazaki H., Abe Y., Suemizu H., Tsukamoto H., et al. The modifier subunit of glutamate cysteine ligase (GCLM) is a molecular target for amelioration of cisplatin resistance in lung cancer. Int J Oncol 2003, 23:1333-1339.
58. Laffin B., Petrash J.M. Expression of the aldo-ketoreductases AKR1B1 and AKR1B10 in human cancers. Front Pharmacol 2012, 3:104.
59. Sun T., Gao Y., Tan W., Ma S., Shi Y., Yao J., et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007, 39:605-613.
60. Liang C.H., Liu L.F., Shiu L.Y., Huang Y.S., Chang L.C., Kuo K.W. Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells. Biochem Biophys Res Commun 2004, 322:751-758.
61. Suzuki M., Mohamed S., Nakajima T., Kubo R., Tian L., Fujiwara T., et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 2008, 33:113-119.
62. Hartmann T.N., Burger J.A., Glodek A., Fujii N., Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005, 24:4462-4471.
63. Yoshioka K., Nakamori S., Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 1999, 59:2004-2010.
64. Miyamoto C., Maehata Y., Ozawa S., Ikoma T., Kubota E., Izukuri K., et al. Fasudil suppresses fibrosarcoma growth by stimulating secretion of the chemokine CXCL14/BRAK. J Pharmacol Sci 2012, 120:241-249.
65. Cappuzzo F., Marchetti A., Skokan M., Rossi E., Gajapathy S., Felicioni L., et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009, 27:1667-1674.
66. Okuda K., Sasaki H., Yukiue H., Yano M., Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008, 99:2280-2285.
67. Feng Y., Thiagarajan P.S., Ma P.C. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012, 7:459-467.
68. Zhong C.Y., Zhou Y.M., Douglas G.C., Witschi H., Pinkerton K.E. MAPK/AP-1 signal pathway in tobacco smoke-induced cell proliferation and squamous metaplasia in the lungs of rats. Carcinogenesis 2005, 26:2187-2195.
69. Wang X., Long M., Dong K., Lin F., Weng Y., Ouyang Y., et al. Chemotherapy agents induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway. Cancer Biol Ther 2013, 14.:12.
70. Kelleher F.C., O'Sullivan H., Smyth E., McDermott R., Viterbo A. Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis 2013, 34:2198-2205.
71. Fischer H., Taylor N., Allerstorfer S., Grusch M., Sonvilla G., Holzmann K., et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008, 7:3408-3419.
72. Yamayoshi T., Nagayasu T., Matsumoto K., Abo T., Hishikawa Y., Koji T. Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. J Pathol 2004, 204:110-118.
73. Vineis P., Manuguerra M., Kavvoura F.K., Guarrera S., Allione A., Rosa F., et al. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 2009, 101:24-36.
74. Goode E.L., Ulrich C.M., Potter J.D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:1513-1530.
75. Chung-man Ho J., Zheng S., Comhair S.A., Farver C., Erzurum S.C. Differential expression of manganese superoxide dismutase and catalase in lung cancer. Cancer Res 2001, 61:8578-8585.
76. Joo M., Wright J.G., Hu N.N., Sadikot R.T., Park G.Y., Blackwell T.S., et al. Yin Yang 1 enhances cyclooxygenase-2 gene expression in macrophages. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1219-L1226.
77. Crawford E.L., Blomquist T., Mullins D.N., Yoon Y., Hernandez D.R., Al-Bagdhadi M., et al. CEBPG regulates ERCC5/XPG expression in human bronchial epithelial cells and this regulation is modified by E2F1/YY1 interactions. Carcinogenesis 2007, 28:2552-2559.
78. Gessner C., Woischwill C., Schumacher A., Liebers U., Kuhn H., Stiehl P., et al. Nuclear YB-1 expression as a negative prognostic marker in non-small cell lung cancer. Eur Respir J 2004, 23:14-19.
79. Kashihara M., Azuma K., Kawahara A., Basaki Y., Hattori S., Yanagawa T., et al. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer. J Thorac Oncol 2009, 4:1066-1074.
80. Jung C.K., Jung J.H., Park G.S., Lee A., Kang C.S., Lee K.Y. Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol Int 2006, 56:503-509.
81. Benlloch S., Galbis-Caravajal J.M., Alenda C., Peiró F.M., Sanchez-Ronco M., Rodríguez-Paniagua J.M., et al. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases. Ann Oncol 2009, 20:91-97.
82. Comtesse N., Keller A., Diesinger I., Bauer C., Kayser K., Huwer H., et al. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer 2007, 120:2538-2544.
83. Scherf D.B., Dally H., Müller P., Werle-Schneider G., Jäger B., Edler L., et al. Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis. Eur Respir J 2010, 35:381-390.
84. Jin G., Miao R., Hu Z., Xu L., Huang X., Chen Y., et al. Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. Int J Cancer 2009, 124:2172-2178.
85. Kusy S., Potiron V., Zeng C., Franklin W., Brambilla E., Minna J., et al. Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochim Biophys Acta 2005, 1730:66-76.